Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow IMMUCELL CORP /DE/

Get SEC filing alerts via email and in your feed for IMMUCELL CORP /DE/

ICCC

IMMUCELL CORP /DE/

About IMMUCELL CORP /DE/

ImmuCell Corporation specializes in developing and manufacturing animal health products, primarily antibody-based solutions for dairy and beef industries. Its flagship products, First Defense and Re-Tain, focus on preventing calf scours and treating subclinical mastitis. The company leverages proprietary technologies, regulatory approvals, and a global distribution network to deliver innovative, sustainable, and effective solutions that enhance animal health, productivity, and food safety.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from IMMUCELL CORP /DE/

1
1
IMMUCELL CORP /DE/ ImmuCell Corporation Reports 28.4% Increase in Product Sales for Q1 2026

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
IMMUCELL CORP /DE/ ImmuCell Corporation Reports 4.3% Increase in Product Sales and Improved Gross Margin for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
IMMUCELL CORP /DE/ ImmuCell Reports Q3 2025 Financial Results with Improved Gross Margin and Net Operating Income

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
IMMUCELL CORP /DE/ ImmuCell Corporation Reports 17.7% Increase in Product Sales and Net Income Turnaround for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
IMMUCELL CORP /DE/ ImmuCell Corporation Reports Net Income Turnaround and 11% Sales Growth in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
IMMUCELL CORP /DE/ ImmuCell Corporation Reports 52% Increase in Product Sales for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
IMMUCELL CORP /DE/ ImmuCell Corporation Reports 11.4% Revenue Growth, Improved Gross Margins, and Reduced Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments